FY2025 · ended Dec 31, 2025 · Revenue $3.07B, +6.3% YoY · Filed Feb 17, 2026
West Pharmaceutical Services, Inc. (WST) files with the SEC under industry code 3841, Surgical & Medical Instruments & Apparatus. In fiscal 2025, which ended Dec 31, 2025, it reported revenue of $3.1 billion and net income of $493.7 million. Free cash flow was $468.9 million. As of Sep 30, 2026 it held $464.1 million in cash and investments and $313.9 million in total debt.
Revenue (TTM)
$3.40B
+12.6% vs year-ago TTM
Net income (TTM)
$638.90M
+29.9% vs year-ago TTM
Operating cash flow (TTM)
$654.50M
-5.7% vs year-ago TTM
Free cash flow (TTM)
$453.40M
+19.6% vs year-ago TTM
EPS (TTM)
$8.90
+31.9% vs year-ago TTM
Dividend per share
$0.86
+4.9% vs prior year
Shares outstanding
72.02M
-0.4% vs prior year
Net cash
$150.20M
as of Sep 30, 2026
Operating margin
23.0%
FY 2026
Company profile
- Industry
- Surgical & Medical Instruments & Apparatus (SIC 3841)
- Listed as
- WST (NYSE)
- Fiscal year ends
- December 31
- Incorporated in
- PA
- Headquarters
- Exton, PA
- SEC filer status
- Large accelerated filer
- SEC CIK
- 105770
- Former names
- WEST CO INC (until Feb 11, 1999)
Other Surgical & Medical Instruments & Apparatus companies
- Stryker Corp SYK
- 3M Co MMM
- Boston Scientific Corp BSX
- Becton Dickinson & Co BDX
- Medline Inc. MDLN
- Resmed Inc RMD
- Dexcom Inc DXCM
- Fresenius SE & Co. KGaA FSNUY
All 151 Surgical & Medical Instruments & Apparatus companies
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
FY 2023 Dec 31, 2023 |
FY 2022 Dec 31, 2022 |
FY 2021 Dec 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $3.1B | $2.9B | $2.9B | $2.9B | $2.8B |
| Operating income | $584.9M | $569.9M | $676.0M | $734.0M | $752.3M |
| Net income | $493.7M | $492.7M | $593.4M | $585.9M | $661.8M |
| Diluted EPS | $6.79 | $6.69 | $7.88 | $7.73 | $8.67 |
| Operating cash flow | $754.8M | $653.4M | $776.5M | $724.0M | $584.0M |
| Free cash flow | $468.9M | $276.4M | $414.5M | $439.4M | $330.6M |
| Total assets | $4.3B | $3.6B | $3.8B | $3.6B | $3.3B |
| Total liabilities | $1.1B | $961.1M | $948.5M | $931.9M | $978.4M |
| Stockholders' equity | $3.2B | $2.7B | $2.9B | $2.7B | $2.3B |
| Cash and investments | $791.3M | $484.6M | $853.9M | $894.3M | $762.6M |
| Total debt | $326.2M | $305.3M | $309.0M | $317.9M | $325.3M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 10-Q | Quarterly report | Oct 29, 2026 | Sep 30, 2026 |
| 8-K |
Current report
Results of operations, Regulation FD disclosure
|
Oct 29, 2026 | Oct 29, 2026 |
| 8-K |
Current report
Material agreement, Agreement ended, New debt
|
Oct 26, 2026 | Oct 26, 2026 |
| 10-Q | Quarterly report | Jul 23, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations, Regulation FD disclosure
|
Jul 23, 2026 | Jul 23, 2026 |
| 8-K |
Current report
Material agreement
|
Jul 14, 2026 | Jul 14, 2026 |
All 1001 West Pharmaceutical Services, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.